title: Hypothalamic GABAA receptor blockade modulates cerebral cortical systems sensitive to acute stressors.
abstract: Pharmacologic blockade of GABA binding sites in the hypothalamus elicits a pattern of physiological and behavioral arousal. The latter outcome implicates a perturbation in the neural functioning of higher brain centers. The effect that hypothalamic GABAA receptor modulation has on the function of cerebral cortical neural substrates linked with responses to stressors was assessed using microinfusion of bicuculline methiodide (BMI) into the medial hypothalamus of freely moving, handling habituated rats. BMI led to rapid increases in frontal cortical dopamine (DA) utilization (calculated from the sum of the levels of the DA metabolites, homovanilic and dihydroxyphenylacetic acids, divided by DA levels) resembling that identified following restraint-induced stress. Also, cortical GABAA receptor function [using chloride (Cl-) enhancement of 3H-flunitrazepam (Flu) binding as an index] was disrupted; i.e. there was a loss of typical Cl- enhancement of 3H-Flu binding in animals after BMI infusions. However, placing animals in restraint after BMI infusion reversed the effects of BMI, with both DA utilization and Cl- facilitated 3H-Flu binding similar to control basal values. Muscimol infusions in separately prepared animals did not alter either frontal cortical DA utilization or GABAA receptor function. The present results implicate GABA in the hypothalamus as "gating" activity of cortical systems involved in sensation of and/or responses to stressors. These findings may have important implications for effects of autonomic arousal on neural substrates involved in mediating stress responses.
authors.affiliation: Department of Neurobiology and Anatomy, University of Rochester, New York 14642.
authors.forename: J R
authors.initials: JR
authors.lastname: Inglefield
authors.forename: C K
authors.initials: CK
authors.lastname: Kellogg
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001640:Bicuculline / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects; D002540:Cerebral Cortex / Q000378:metabolism / Q000503:physiopathology*; D002712:Chlorides / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D005445:Flunitrazepam / Q000494:pharmacology; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051381:Rats; D013315:Stress, Psychological / Q000503:physiopathology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology
chemical_list: D002712:Chlorides; D058785:GABA-A Receptor Agonists; D058787:GABA-A Receptor Antagonists; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam; D004298:Dopamine; D001640:Bicuculline